Vivian A. Fonseca, MD, FRCP
Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has served on the ADA Board of Directors and several committees. He has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology. He has served on committees writing guidelines for both organizations. He has held a leadership role and served on various committees in several other organizations including the American Board of Internal Medicine. He has received several awards including Banting Medal for Leadership and Service from The American Diabetes Association, the Seale - Harris award from the Southern Medical Association, the Gerald Reaven award from the World Congress in Insulin Resistance and 2024 Mentor of the Year award and 2025 Founders Medal from SSCI. He has received several teaching awards and was elected to the Alpha Omega Alpha Honor Medical Society and has been listed for several years among the Best Doctors in the USA and for several years rated by Expertscape among the top 10 experts in Diabetes worldwide. Dr. Fonseca is a fellow of the Royal College of Physicians (London).
He plays a significant role in Clinical Research as Assistant Dean at Tulane University, and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) Program. Dr Fonseca has served as Associate Director of the Aging and Cardiometabolic COBREs and a mentor and committee member in BIRCWH, and the COBRE in Sex Based Precision Medicine. He has strong interest in facilitating clinical research and developing the next generation of translational researchers. He is the Medical Director of the Tulane Clinical Trials Unit and Director of the Research Professional Development Core, which runs the Masters in Science in Clinical Research degree course.
He has had several roles as editor of scientific journals including Editor in chief of Diabetes Care, (2007-2011 having formerly been associate editor); Journal of the Metabolic Syndrome (2002-2006); Journal of Diabetes and its Complications; and currently Editor of Endocrine Research. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism, and is an ad hoc reviewer for several leading journals, including New England Journal of Medicine, Lancet, JAMA, Diabetes, etc.
Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. His research program is active in the development and use of a novel diabetes risk engine (BRAVO) in clinical practice; developing new treatment approaches in diabetes, evaluating inflammation in diabetes, and using technology to improve diabetes care in underprivileged populations. He is Co – PI of REACHNET a large network that conducts research utilizing electronic health records of over 3 million people across several states. He is the site PI of several large national research programs including 1. the All of Us Program, 2. COVID related studies – N3C utilizing EMR data about COVID and the RECOVER study which will evaluate long term COVID complications in a large cohort.
Dr. Fonseca has lectured in the United States and abroad. He has published over 500 papers and review articles, with an H- index of 100. He is the editor of the text book “Clinical Diabetes: Translating Research into Practice” (El Sevier) and several monographs and book chapters.
16
Talks
14.0k
Listens
Talks
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes
September 13, 2026
Share
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes
Combination Gut Hormone therapy for type 2 Diabetes - Cagrilintide–semaglutide (CagriSema) versus...
September 12, 2026
Share
Combination Gut Hormone therapy for type 2 Diabetes - Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2)